Know Cancer

or
forgot password

Detection of Hairy Cell Leukemia Minimal Residual Disease: Detection by Flow Cytometry


N/A
18 Years
N/A
Not Enrolling
Both
Leukemia

Thank you

Trial Information

Detection of Hairy Cell Leukemia Minimal Residual Disease: Detection by Flow Cytometry


OBJECTIVES: I. Compare the sensitivity of flow cytometry, immunohistochemistry, and
polymerase chain reaction in detecting minimal residual disease following therapy with
cladribine in patients with hairy cell leukemia.

OUTLINE: Blood and bone marrow samples are obtained from patients at time of bone marrow
biopsies to assess minimal residual disease using flow cytometry, immunohistochemistry, and
polymerase chain reaction. Patients are followed for 2 years or until disease relapse.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study over 12-24 months.

Inclusion Criteria


DISEASE CHARACTERISTICS: Clinically documented hairy cell leukemia Active or in remission
Must have received prior cladribine and be undergoing bone marrow biopsies as follow up

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Not specified Life expectancy:
Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No prior chemotherapy following prior cladribine Endocrine therapy: Not
specified Radiotherapy: Not specified Surgery: Not specified

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Loann C. Peterson, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Robert H. Lurie Cancer Center

Authority:

United States: Federal Government

Study ID:

NU 97Z3

NCT ID:

NCT00005619

Start Date:

February 2000

Completion Date:

August 2001

Related Keywords:

  • Leukemia
  • progressive hairy cell leukemia, initial treatment
  • refractory hairy cell leukemia
  • Leukemia
  • Leukemia, Hairy Cell
  • Neoplasm, Residual

Name

Location
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois  60611